HIMS

HIMS

USD

Hims & Hers Health Inc. Class A Common Stock

$44.070-1.680 (-3.672%)

Preço em tempo real

Healthcare
Drug Manufacturers - Specialty & Generic
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$45.750

Máximo

$48.340

Mínimo

$43.620

Volume

36.16M

Fundamentos da empresa

Capitalização de mercado

10.0B

Setor

Drug Manufacturers - Specialty & Generic

País

United States

Estatísticas de negociação

Volume médio

28.91M

Bolsa de valores

NYQ

Moeda

USD

Faixa de 52 semanas

Mínimo $19.15Atual $44.070Máximo $72.98

Notícias relacionadas

Analyst Upgrades

B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $32

B of A Securities analyst Allen Lutz maintains Hims & Hers Health with a Underperform and raises the price target from $28 to $32.

Ver mais
B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $32
Reuters

Futures tumble after Wall St banks warn of market pullback, Palantir slides

U.S. stock futures tumbled on Tuesday as investors questioned lofty valuations in the technology sector after top Wall Street banks warned of a stock market selloff and AI darling Palantir's sales forecast failed to lift the mood.

Ver mais
Futures tumble after Wall St banks warn of market pullback, Palantir slides
Analyst Upgrades

BTIG Reiterates Buy on Hims & Hers Health, Maintains $85 Price Target

BTIG analyst David Larsen reiterates Hims & Hers Health with a Buy and maintains $85 price target.

Ver mais
BTIG Reiterates Buy on Hims & Hers Health, Maintains $85 Price Target
Reuters

Hims and Hers beats revenue estimates on strong subscriber growth

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings.

Ver mais
Hims and Hers beats revenue estimates on strong subscriber growth
BusinessWire

Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3

Ver mais
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results
PR Newswire

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.

A securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) is pending. The lawsuit was filed by Glancy Prongay & Murray...

Analyst Upgrades

Keybanc Initiates Coverage On Hims & Hers Health with Sector Weight Rating

Keybanc analyst Justin Patterson initiates coverage on Hims & Hers Health with a Sector Weight rating.

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.